Nimesulide Ratiopharm and Flexiban
PreclinicalSmall molecule
Nimesulide Ratiopharm and Flexiban is one of 19 small molecule programs targeting Temporomandibular Joint Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Temporomandibular Joint Disorder
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsApproved
Nurtec
PfizerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Aimovig
AmgenPhase 2
Pamelor
SSpecgx
Phase 2
Cecon
MMcGuff Pharmaceuticals, Inc.
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Roma La Sapienza